IN2004MU00133A - - Google Patents

Download PDF

Info

Publication number
IN2004MU00133A
IN2004MU00133A IN133MU2004A IN2004MU00133A IN 2004MU00133 A IN2004MU00133 A IN 2004MU00133A IN 133MU2004 A IN133MU2004 A IN 133MU2004A IN 2004MU00133 A IN2004MU00133 A IN 2004MU00133A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Shlomit Wizel
Marina Yu Etinger
Michael Yuzefovich
Ben-Zion Dolitzky
Valerie Niddam-Hildesheim
Judith Aronhime
Boris Pertsikov
Gennady A Nisnevich
Boris Tishin
Dina Blasberger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2004MU00133A publication Critical patent/IN2004MU00133A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
IN133MU2004 2001-09-07 2004-02-20 IN2004MU00133A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31785001P 2001-09-07 2001-09-07
US34227301P 2001-12-21 2001-12-21
US38650502P 2002-06-05 2002-06-05
US40383802P 2002-08-14 2002-08-14

Publications (1)

Publication Number Publication Date
IN2004MU00133A true IN2004MU00133A (ko) 2005-04-29

Family

ID=27502150

Family Applications (2)

Application Number Title Priority Date Filing Date
IN133MU2004 IN2004MU00133A (ko) 2001-09-07 2004-02-20
IN429MU2006 IN2006MU00429A (ko) 2001-09-07 2006-04-13

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN429MU2006 IN2006MU00429A (ko) 2001-09-07 2006-04-13

Country Status (16)

Country Link
US (2) US6849736B2 (ko)
EP (1) EP1436295A4 (ko)
JP (2) JP5043286B2 (ko)
KR (1) KR100774271B1 (ko)
CN (1) CN1551880A (ko)
CA (1) CA2457835A1 (ko)
CZ (1) CZ2004446A3 (ko)
HR (1) HRP20040321A2 (ko)
HU (1) HUP0500753A3 (ko)
IL (1) IL160721A0 (ko)
IN (2) IN2004MU00133A (ko)
MX (1) MXPA04002192A (ko)
NO (1) NO20041449L (ko)
PL (1) PL374179A1 (ko)
SK (1) SK1592004A3 (ko)
WO (1) WO2003022209A2 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
KR20050044449A (ko) * 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르의 합성 및 정제 방법
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
DE60307494D1 (de) * 2002-10-16 2006-09-21 Teva Pharma Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
ES2246034T3 (es) * 2003-12-09 2006-02-01 Helm Ag Formulacion farmaceutica de valaciclovir.
EP1761535A1 (en) * 2004-06-30 2007-03-14 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2006035452A1 (en) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Novel pseudomorph of valaciclovir hydrochloride
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US7872075B2 (en) * 2005-10-07 2011-01-18 Exxonmobil Chemical Patents Inc. Peroxide-cured thermoplastic vulcanizates and process for making the same
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
CR20200220A (es) 2013-11-15 2020-11-18 Akebia Therapeutics Inc FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ATE199719T1 (de) * 1993-06-10 2001-03-15 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
US5856481A (en) * 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
PT874631E (pt) * 1996-01-19 2004-04-30 Glaxo Group Ltd Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
KR20050044449A (ko) * 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르의 합성 및 정제 방법
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Also Published As

Publication number Publication date
KR20040036932A (ko) 2004-05-03
SK1592004A3 (sk) 2005-03-04
MXPA04002192A (es) 2005-02-17
US20050187229A1 (en) 2005-08-25
US6849736B2 (en) 2005-02-01
IN2006MU00429A (ko) 2007-08-17
WO2003022209A2 (en) 2003-03-20
WO2003022209A9 (en) 2004-04-08
JP2012162565A (ja) 2012-08-30
US20030114470A1 (en) 2003-06-19
JP5043286B2 (ja) 2012-10-10
EP1436295A4 (en) 2007-07-11
CZ2004446A3 (cs) 2005-01-12
IL160721A0 (en) 2004-08-31
PL374179A1 (en) 2005-10-03
CA2457835A1 (en) 2003-03-20
EP1436295A2 (en) 2004-07-14
KR100774271B1 (ko) 2007-11-08
JP2005526694A (ja) 2005-09-08
HRP20040321A2 (en) 2004-08-31
HUP0500753A3 (en) 2006-05-29
HUP0500753A2 (hu) 2005-11-28
WO2003022209A3 (en) 2003-11-27
NO20041449L (no) 2004-04-06
CN1551880A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
BE2017C057I2 (ko)
BE2017C051I2 (ko)
BE2017C032I2 (ko)
BE2016C051I2 (ko)
BE2015C077I2 (ko)
BE2015C046I2 (ko)
BE2014C052I2 (ko)
BE2014C036I2 (ko)
BE2014C026I2 (ko)
BE2014C004I2 (ko)
BE2012C022I2 (ko)
BE2017C050I2 (ko)
BE2011C034I2 (ko)
BE2007C047I2 (ko)
AU2002307149A8 (ko)
BRPI0209186B1 (ko)
IN2006MU00429A (ko)
BE2014C008I2 (ko)
BRPI0204884B1 (ko)
BE2016C021I2 (ko)
BE2017C059I2 (ko)
JP2002159009A5 (ko)
BRPI0101486B8 (ko)
BE2012C051I2 (ko)
AU2000280389A8 (ko)